Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 15/20 | 0.43 |
| ▸ | CHRM2 known ✓ | P08172 | 10/20 | 0.43 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.43 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1996228 | 1.00 | CHRM3 (0.43) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| Bromide SCHEMBL2335688 | 1.00 | CHRM3 (0.43) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| Bromide SCHEMBL5395427 | 0.99 | CHRM3 (0.43) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| Bromide SCHEMBL5388585 | 0.99 | CHRM3 (0.43) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1707214 | 0.99 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2340421 | 0.99 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5473748 | 0.99 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8449813 | 0.98 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| Iodide SCHEMBL5386794 | 0.98 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL7142072 | 0.98 | CHRM3 (0.42) | CHRM3CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6204285-B1 | RESULTING FROM BLADDER DETRUSOR MUSCLE INSTABILITY | SEPRACOR INC. | 2001-03-20 | — | — | US | claimed |
| US-12616654-B2 | Stainless steel can for pressurised metered dose inhalers | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-05 | — | — | US | disclosed |
| US-12383491-B2 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | AZURITY PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250082588-A1 | PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-03-13 | — | — | US | disclosed |
| US-20240189222-A1 | READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE | SLAYBACK PHARMA LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-11938217-B2 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | SLAYBACK PHARMA LLC (US) | 2024-03-26 | — | — | US | disclosed |
| EP-3415127-B1 | TOPICAL GLYCOPYRROLATE FORMULATIONS AND A WIPE CONTAINING THEREOF | ROSE U LLC (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023227781-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-30 | — | — | WO | disclosed |
| US-20230277451-A1 | A PHARMACEUTICAL FORMULATION FOR PRESSURISED METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-09-07 | — | — | US | disclosed |
| US-20230270631-A1 | TOPICAL GLYCOPYRROLATE FORMULATIONS | SWK FUNDING LLC | 2023-08-31 | — | — | US | disclosed |
| US-20120022127-A1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | NOVARTIS AG (CH) | 2012-01-26 | — | — | US | disclosed |
| US-20100276329-A1 | TOPICAL GLYCOPYRROLATE FORMULATIONS | DERMIRA, INC. | 2010-11-04 | — | — | US | disclosed |
| US-7816396-B1 | Method for increasing the bioavailability of glycopyrrolate | SHIONOGI PHARMA, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7638552-B1 | Method for increasing the bioavailability of glycopyrrolate | SCIELE PHARMA, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090156562-A1 | NOVEL COLORED SOLUTIONS OF INJECTABLE DRUGS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | WINCH PETER D | 2009-06-18 | — | — | US | disclosed |
| US-20090005577-A1 | Method of producing 1-substituted 3-pyrrolates | KRAIOUCHKINE NIKOLAI | 2009-01-01 | — | — | US | disclosed |
| US-20080317832-A1 | TRANSDERMAL DELIVERY SYSTEM COMPRISING GLYCOPYRROLATE TO TREAT SIALORRHEA | SCIELE PHARMA, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080260823-A1 | ORALLY DISINTEGRATING TABLET COMPRISING GLYCOPYRROLATE FOR TREATING SIALORRHEA | SCIELE PHARMA, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7091236-B1 | Method for increasing the bioavailability of glycopyrrolate | SCIELE PHARMA, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-6063808-A | Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate | SEPRACOR INC. (US) | 2000-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005577-A1 | Method of producing 1-substituted 3-pyrrolates | GYPA, GIPR, PGA5 | CHRM3 129/4885CHRM2 459/4885CHRM4 277/4885 |
| US-12616654-B2 | Stainless steel can for pressurised metered dose inhalers | CHRM5, CHRM3, CHRM2 | CHRM3 2/4885CHRM2 3/4885CHRM4 5/4885 |
| US-20230270631-A1 | TOPICAL GLYCOPYRROLATE FORMULATIONS | WAPL, GALE, GYPA | CHRM3 132/4885CHRM2 129/4885CHRM4 230/4885 |
| US-20240189222-A1 | READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE | CHRNA5, CHRNB4, CHRNB1 | CHRM3 15/4885CHRM2 18/4885CHRM4 20/4885 |
| US-20120022127-A1 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS | C1S, C1R, C9 | CHRM3 616/4885CHRM2 172/4885CHRM4 731/4885 |
| US-20100276329-A1 | TOPICAL GLYCOPYRROLATE FORMULATIONS | WAPL, GALE, GYPA | CHRM3 132/4885CHRM2 129/4885CHRM4 230/4885 |
| US-20090156562-A1 | NOVEL COLORED SOLUTIONS OF INJECTABLE DRUGS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | CYP3A5, IK, ACHE | CHRM3 12/4885CHRM2 10/4885CHRM4 11/4885 |
| US-12383491-B2 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | CHRNA5, CHRNB4, CHRNB1 | CHRM3 15/4885CHRM2 18/4885CHRM4 20/4885 |
| US-11938217-B2 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | CHRNA5, CHRNB4, CHRNB1 | CHRM3 15/4885CHRM2 18/4885CHRM4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.